Mesoblast Limited (MSB.AX) Stock Analysis & Winston Score

Mesoblast is an Australian biotechnology company that develops cell-based medicines to treat serious diseases. Its main focus is on using a type of adult stem cell, called mesenchymal precursor cells, to reduce dangerous inflammation in the body. Its lead product, Ryoncil, was approved by the U.S. FDA in 2024 for a rare and life-threatening condition in children called steroid-refractory acute graft versus host disease, which can occur after bone marrow transplants. Mesoblast earns revenue through product sales and partnership agreements with larger pharmaceutical companies, though it currently spends far more than it earns, as shown by its deeply negative margins. The company operates primarily in the United States and Australia, with research and commercial activities centered on a small number of late-stage drug candidates. Its main competitive edge is its proprietary cell therapy platform, but the key risk is its ongoing need to raise cash to fund operations while it works to grow sales of Ryoncil and advance its pipeline.